Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotechnology company focused on adaptive immune system genetics and clinical products, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.
The company's management will deliver their presentation on Tuesday, January 14th at 5:15 p.m. Pacific Time / 8:15 p.m. Eastern Time. Investors and interested parties can access both live and archived versions of the presentation through the 'Investors' section on the company's website at www.adaptivebiotech.com.
Adaptive Biotechnologies (Nasdaq: ADPT), un'azienda biotecnologica in fase commerciale focalizzata sulla genetica del sistema immunitario adattivo e sui prodotti clinici, ha annunciato la sua partecipazione al 43° Annuale J.P. Morgan Healthcare Conference a San Francisco.
La gestione dell'azienda presenterà il loro intervento martedì 14 gennaio alle 17:15 ora del Pacifico / 20:15 ora dell'Est. Gli investitori e le parti interessate possono accedere sia alle versioni in diretta sia a quelle archiviate della presentazione attraverso la sezione 'Investitori' del sito web dell'azienda all'indirizzo www.adaptivebiotech.com.
Adaptive Biotechnologies (Nasdaq: ADPT), una empresa de biotecnología en etapa comercial centrada en la genética del sistema inmunológico adaptativo y productos clínicos, ha anunciado su participación en la 43ª Conferencia Anual de Atención Médica J.P. Morgan en San Francisco.
La dirección de la empresa realizará su presentación el martes 14 de enero a las 5:15 p.m. hora del Pacífico / 8:15 p.m. hora del Este. Los inversores y partes interesadas pueden acceder tanto a las versiones en vivo como a las archivadas de la presentación a través de la sección 'Inversores' en el sitio web de la empresa en www.adaptivebiotech.com.
Adaptive Biotechnologies (Nasdaq: ADPT), 적응형 면역 시스템 유전학 및 임상 제품에 집중하는 상업 단계의 생명공학 회사가 샌프란시스코에서 열리는 제43회 J.P. 모건 헬스케어 컨퍼런스에 참가한다고 발표했습니다.
회사의 경영진은 1월 14일 화요일 오후 5:15 (태평양 표준시) / 오후 8:15 (동부 표준시)에 발표를 진행할 예정입니다. 투자자와 관심 있는 분들은 회사 웹사이트 www.adaptivebiotech.com의 '투자자' 섹션을 통해 발표의 실시간 및 기록된 버전을 모두 엑세스할 수 있습니다.
Adaptive Biotechnologies (Nasdaq: ADPT), une entreprise biotechnologique en phase commerciale axée sur la génétique du système immunitaire adaptatif et les produits cliniques, a annoncé sa participation à la 43e Conférence Annuelle sur les Soins de Santé J.P. Morgan à San Francisco.
La direction de l'entreprise présentera son intervention mardi 14 janvier à 17h15 heure du Pacifique / 20h15 heure de l'Est. Les investisseurs et les parties intéressées peuvent accéder à la fois à la version en direct et aux versions archivées de la présentation via la section 'Investisseurs' sur le site web de l'entreprise à www.adaptivebiotech.com.
Adaptive Biotechnologies (Nasdaq: ADPT), ein biotechnologisches Unternehmen in der kommerziellen Phase, das sich auf die Genetik des adaptiven Immunsystems und klinische Produkte konzentriert, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Conference in San Francisco bekannt gegeben.
Das Management des Unternehmens wird seine Präsentation am Dienstag, dem 14. Januar um 17:15 Uhr Pazifischer Zeit / 20:15 Uhr Eastern Time halten. Investoren und interessierte Parteien können sowohl auf die Live- als auch auf die archivierten Versionen der Präsentation über den Bereich 'Investoren' auf der Unternehmenswebsite unter www.adaptivebiotech.com zugreifen.
- None.
- None.
SEATTLE, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Adaptive Biotechnologies’ management is scheduled to present on Tuesday, January 14th at 5:15 p.m. Pacific Time / 8:15 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Director, Corporate Communications
206-279-2423
media@adaptivebiotech.com
FAQ
When is Adaptive Biotechnologies (ADPT) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Adaptive Biotechnologies' (ADPT) J.P. Morgan Healthcare Conference presentation?
What is the focus of Adaptive Biotechnologies' (ADPT) business?
Which healthcare conference is Adaptive Biotechnologies (ADPT) participating in for January 2025?
